Literature DB >> 17416851

Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group.

Gordon J Rustin1, Graham M Mead, Sally P Stenning, Paul A Vasey, Nina Aass, Robert A Huddart, Michael P Sokal, Jonathan K Joffe, Stephen J Harland, Sarah J Kirk.   

Abstract

PURPOSE: Surveillance is a standard management approach for stage I nonseminomatous germ cell tumors (NSGCT). A randomized trial of two versus five computed tomography (CT) scans was performed to determine whether the number of scans influenced the proportion of patients relapsing with intermediate- or poor-prognosis disease at relapse.
METHODS: Patients with clinical stage I NSGCT opting for surveillance were randomly assigned to chest and abdominal CT scans at either 3 and 12 or 3, 6, 9, 12, and 24 months, with all other investigations identical in the two arms. Three of five patients were allocated to the two-scan schedule. Four hundred patients were required.
RESULTS: Two hundred forty-seven patients were allocated to a two-scan and 167 to five-scan policy. With a median follow-up of 40 months, 37 relapses (15%) have occurred in the two-scan arm and 33 (20%) in the five-scan arm. No patients had poor prognosis at relapse, but two (0.8%) of those relapsing in the two-scan arm had intermediate prognosis compared with 1 (0.6%) in the five-scan arm, a difference of 0.2% (90% CI, -1.2% to 1.6%). No deaths have been reported.
CONCLUSION: This study can rule out with 95% probability an increase in the proportion of patients relapsing with intermediate- or poor-prognosis disease of more than 1.6% if they have two rather than five CT scans as part of their surveillance protocol. CT scans at 3 and 12 months after orchidectomy should be considered a reasonable option in low-risk patients.

Entities:  

Mesh:

Year:  2007        PMID: 17416851     DOI: 10.1200/JCO.2006.08.4889

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  35 in total

Review 1.  [What is new in 2011 regarding testicular cancer].

Authors:  S Krege
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

Review 2.  Controversies in the management of early-stage germ cell tumors.

Authors:  Ann Tan; Timothy Gilligan
Journal:  Curr Oncol Rep       Date:  2009-05       Impact factor: 5.075

Review 3.  Current Concepts in Management of Stage I NSGCT.

Authors:  Puneet Ahluwalia; Gagan Gautam
Journal:  Indian J Surg Oncol       Date:  2016-12-17

4.  SEOM guidelines: non-seminomatous germ cell cancer (NSGCC).

Authors:  Pablo Maroto; Xavier Garcí Del Muro; Javier Sastre; Dolores Isla
Journal:  Clin Transl Oncol       Date:  2011-08       Impact factor: 3.405

5.  High risk NSGCT: case for surveillance.

Authors:  David Michael Kakiashvili; Alvaro Zuniga; Michael A S Jewett
Journal:  World J Urol       Date:  2009-07-16       Impact factor: 4.226

Review 6.  Clinical stage I seminoma: the case for surveillance.

Authors:  Nathan Lawrentschuk; Neil Fleshner
Journal:  World J Urol       Date:  2009-06-11       Impact factor: 4.226

7.  Patients with testicular cancer undergoing CT surveillance demonstrate a pitfall of radiation-induced cancer risk estimates: the timing paradox.

Authors:  Pari V Pandharipande; Jonathan D Eisenberg; Richard J Lee; Michael E Gilmore; Ekin A Turan; Sarabjeet Singh; Mannudeep K Kalra; Bob Liu; Chung Yin Kong; G Scott Gazelle
Journal:  Radiology       Date:  2012-12-18       Impact factor: 11.105

8.  Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis.

Authors:  Soner Guney; Nese Guney; Nurettin Cem Sonmez; Erbil Ergenekon
Journal:  Med Oncol       Date:  2008-09-26       Impact factor: 3.064

9.  Management options for stage 1 nonseminomatous germ cell tumors of the testis.

Authors:  Stephen D W Beck
Journal:  Indian J Urol       Date:  2010 Jan-Mar

Review 10.  Management of stage I testicular germ cell tumours.

Authors:  Michal Chovanec; Nasser Hanna; K Clint Cary; Lawrence Einhorn; Costantine Albany
Journal:  Nat Rev Urol       Date:  2016-09-13       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.